Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Silence Therapeutics (SLN – Research Report) and keeping the price target at $75.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Patrick Trucchio has given his Buy rating due to a combination of factors that highlight Silence Therapeutics’ strategic positioning and potential for growth. The company has demonstrated focused execution and strategic capital management, extending its financial runway into 2028. This financial stability is complemented by the advancement of its clinical pipeline, particularly with zerlasiran, which is moving towards Phase 3 readiness for Lp(a) lowering, supported by regulatory alignment in major markets and active partnership discussions.
Furthermore, Silence Therapeutics is progressing with divesiran in polycythemia vera, with significant upcoming data presentations and trial enrollments. The collaboration with AstraZeneca and the initiation of trials for SLN548 in complement-mediated diseases also add to the company’s promising outlook. With a robust RNA interference platform and multiple catalysts on the horizon, including potential partnerships and trial initiations, Silence Therapeutics is well-positioned for significant upside, justifying the Buy rating and a price target of $75.
In another report released today, Morgan Stanley also maintained a Buy rating on the stock with a $25.00 price target.